- Report
- October 2022
- 194 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- July 2020
- 100 Pages
Global
From €3494EUR$3,675USD£2,935GBP
- Report
- November 2022
- 125 Pages
Global
From €2367EUR$2,490USD£1,989GBP
- Report
- December 2022
- 77 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- January 2023
- 343 Pages
Global
From €3327EUR$3,500USD£2,795GBP
€4753EUR$5,000USD£3,993GBP
- Report
- August 2021
- 77 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- January 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
From €1901EUR$2,000USD£1,597GBP
- Report
- November 2023
- 150 Pages
Global
From €4230EUR$4,450USD£3,554GBP
- Report
- November 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- August 2023
- 114 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- February 2024
- 159 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- March 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- January 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- February 2024
- 173 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- April 2023
- 120 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- October 2023
- 128 Pages
North America
From €3803EUR$4,000USD£3,195GBP
- Report
- October 2023
- 188 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 189 Pages
Global
From €4278EUR$4,500USD£3,594GBP

In the landscape of vaccines, mRNA (messenger RNA) vaccines represent a novel technology that has garnered substantial attention for its role in rapid vaccine development. These vaccines operate by instructing cells to produce a protein that triggers an immune response without using a live virus. This innovative approach stands out for its ability to be developed and scaled up swiftly in response to infectious diseases, offering a flexible platform for vaccine creation. While traditional vaccine development may take years of research and testing, mRNA vaccines can be designed once the genetic information of a pathogen is known.
The adoption of mRNA vaccines has been driven by their potential to address a broad spectrum of diseases beyond just infectious agents. Research is being conducted into their applicability in treating and preventing cancers, genetic disorders, and autoimmune diseases. This expansion of mRNA technology into various medical domains has contributed to the diversification of the vaccine industry.
Several prominent companies are active in the mRNA vaccines market, shaping its trajectory with their research and development efforts. Notable firms include Moderna, Pfizer in collaboration with BioNTech, and CureVac. These companies have invested heavily in mRNA technology, leading to advances that have solidified their positions as key players in the pharmaceutical and biotechnology sectors. Show Less Read more